Skip to content

Effects of Low-Concentration Sevoflurane on Eating Behavior and Bowel Habits in Children with Autism Spectrum Disorder: A Retrospective Self-Controlled Cohort Study

Effects of Low-Concentration Sevoflurane on Eating Behavior and Bowel Habits in Children with Autism Spectrum Disorder: A Retrospective Self-Controlled Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122068
Enrollment
Unknown
Registered
2026-04-08
Start date
2026-04-20
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Observation group:None

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 8 Years

Inclusion criteria

Inclusion criteria: 1.Age 2 to 8 years at the time of inclusion; 2.Diagnosis of Autism Spectrum Disorder (ASD) according to DSM-5 or equivalent clinical diagnosis, with moderate to severe severity (e.g., baseline CARS >= 30 or clinical assessment); 3.Previously received at least one session of low-concentration sevoflurane treatment at our center, with adequate medical records documenting treatment dates, dose/concentration and duration; 4.Availability of at least one of the following at both baseline (T0) and early follow-up (T1, preferably 7–30 days post-treatment): Children’s Eating Behavior Questionnaire (CEBQ) or a 3-day dietary record, and bowel habit records/notes; 5.Parental/guardian consent for retrospective analysis of de-identified records as required by the institutional IRB.

Exclusion criteria

Exclusion criteria: 1.Presence of significant somatic disease that may directly affect feeding or gastrointestinal function (e.g., congenital GI malformations, active inflammatory bowel disease, progressive metabolic disorders); 2.Major infection, surgery, or other acute events within 30 days before T0 or during the treatment period that could substantially alter laboratory or clinical outcomes; 3.Prior fecal microbiota transplantation (FMT) or ongoing long-term probiotic/prebiotic therapy within 30 days if such interventions would confound results and cannot be adequately adjusted for; 4.Insufficient medical records preventing retrieval of key outcome data (missing both T0 and T1 eating or bowel records and lacking any laboratory data); 5.Severe neurological comorbidity (e.g., uncontrolled generalized epilepsy) or other conditions judged by clinicians to preclude inclusion in the retrospective analysis.

Design outcomes

Primary

MeasureTime frame
Children’s Eating Behavior Questionnaire (CEBQ) — Food Selectivity subscale score;Wexner constipation severity score;Autism Behavior Checklist (ABC) score;

Secondary

MeasureTime frame
Childhood Autism Rating Scale (CARS) score;Complete Blood Count;Stool routine;Blood biochemistry;

Countries

China

Contacts

Public ContactTian Hang

Guangzhou Women and Children's Medical Center

tianhang2544@126.com+86 189 0226 8146

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026